There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on RedHill Biopharma (RDHL) and Editas Medicine Inc (EDIT) with bullish sentiments.
RedHill Biopharma (RDHL)
H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on RedHill Biopharma today and set a price target of $16. The company’s shares closed yesterday at $7.97.
According to TipRanks.com, Ramakanth has 0 stars on 0-5 star ranking scale with an average return of -9.2% and a 33.0% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Gritstone Oncology Inc.
RedHill Biopharma has an analyst consensus of Moderate Buy, with a price target consensus of $16.50.
See today’s analyst top recommended stocks >>
Editas Medicine Inc (EDIT)
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Editas Medicine Inc today and set a price target of $55. The company’s shares closed yesterday at $24.68.
Livshits said:
“We remind, EDIT-101 would be the 1st CRISPR-based gene editing therapy to be dosed in humans. Beyond LCA10, Editas plans to have a lead candidate ready for IND-enabling studies for its follow-on ocular gene editing program in Usher syndrome type 2A (USH2A) by end-19. Editas’ collaborators presented preclinical proof-of-concept data on exon skipping as a mechanism to treat Gene & Cell Therapy (ASGCT) annual meeting last week. Those data focused on engineered mouse models and we understand Editas is currently working on an in vivo editing pharmacology package to support selection of a lead candidate. We expect these USH2A studies will largely look like those of EDIT-101, given that the 2 programs use the same vector, promoter and nuclease.”
According to TipRanks.com, Livshits is a 2-star analyst with an average return of 0.4% and a 44.4% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics Inc, Crispr Therapeutics AG, and Intellia Therapeutics.
Editas Medicine Inc has an analyst consensus of Strong Buy, with a price target consensus of $39.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
